Loyola announces 36-hour drill to test response to flu outbreak

NewsGuard 100/100 Score

Loyola University Health System (LUHS) will conduct a 36-hour drill to test its ability to quickly and efficiently respond to a deadly disease outbreak by inoculating its staff against the flu.

The drill begins at 6:30 a.m. Thursday, Oct. 16 and will continue until 6:30 p.m., Friday, Oct. 17. The drill will take place at the system's 61-acre campus in Maywood and at its 28 primary and specialty care facilities in Cook, Will and DuPage counties. Media are welcome to attend.

The drill will also allow the system to vaccinate a significant portion of its 7,825 employees as part of its mandatory policy designed to improve the safety of patients, visitors, staff and their families.

Last year, 99.3 percent of Loyola's staff received flu shots, among the highest percentage of any medical center in the nation. Loyola was among the first medical centers to make flu shots mandatory.

"The flu shot is safe and effective. It reduces infections and absenteeism among employees, prevents transmission to patients and reduces patient hospitalization and mortality," said Dr. Jorge Parada, medical director of infection control, LUHS. "We are committed to taking the right steps to minimize risk to our patients and our employees."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Promising influenza drug candidate shows activity against resistant variants